🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Pfizer Limited PFIZER NIFTY_SMALLNSEPHARMA

Healthcare · Drug Manufacturers - General · India
https://www.pfizerltd.co.in
Company Profile ↓
₹4,609.70
-8.18% 1Y
Mkt Cap₹21,088.33 Cr
P/E29.19
P/B5.31
Div. Yield1.53%
52W High₹5,674.44
52W Low₹4,334.58
Book Value₹918.71
EPS (TTM)₹157.92

Company Overview

Pfizer Limited engages in manufacturing, marketing, trading, and distribution of pharmaceutical products in India and internationally. It offers therapy area and products, such as vaccines, injectables and anti-infectives, inflammation and immunology, and internal medicine for cardiovascular care, oncology, respiratory, multivitamins and multimineral, neuroscience, women's health, gastroenterology, pain management, and nutrition, addressing. The company also offers anti-infectives services to hospitals and nursing homes. It sells its products through a network of independent distributors. Pfizer Limited was incorporated in 1950 and is based in Mumbai, India.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 17.2%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 22.9%.

Reasonable Valuation

Trades at a P/E of 29.2, below the sector median of 41.6.

Healthy Margins

Maintains a net profit margin of 28.7%.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹2,519.27 Cr (+10.4% YoY); net profit ₹722.43 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +10.4%, earnings -5.9%.
  • 5-Year Trend Long-term compounding — revenue CAGR 1.3%, profit CAGR 5.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:1.32%
1 Year:10.45%

Compounded Profit Growth

5 Years:5.01%
1 Year:-5.88%

Stock Price Performance

1 Year:-8.18%
6 Months:-2.53%
3 Months:+2.00%
1 Month:-5.92%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 21% of range
₹4,334.58 ₹5,674.44
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)38.05 · Neutral
Price Performance
1M-5.92%
3M+2.00%
6M-2.53%
1Y-8.18%
Valuation vs Sector

P/E of 29.19 is below the sector median of 41.64 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Healthy ROCE of 22.9%.
  • Excellent profit margin of 28.7%.
  • Generates positive free cash flow.

CONS

  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
29.19
Industry PE
41.64
Forward P/E
22.10
PEG Ratio
-
Book Value
₹918.71
Price to Book
5.31
P/S
8.69
EV/EBITDA
21.30
Dividend Yield
1.53%

Growth (CAGR)

Revenue 5Y
1.32%
Profit 5Y
5.01%
Revenue (YoY)
10.45%
Earnings (YoY)
-5.88%

Profitability & Returns

ROCE
22.94%
ROE
17.19%
ROA
14.68%
Profit Margin
28.68%
Op Margin
33.62%
Gross Margin
64.79%
EPS (Latest Qtr)
₹44.69
EPS (TTM)
₹157.92

Balance Sheet & Liquidity

Debt/Equity
1.67
Quick Ratio
5.31
Current Ratio
6.06
Debt
₹70.23 Cr
Total Assets
₹4,921.88 Cr
Current Assets
₹3,803.22 Cr
Working Capital
₹3,175.74 Cr

Ownership

Promoter Holding
66.95%
Chg in Prom Hold
-0.01%
FII / Inst Holding
17.31%
Chg in FII Hold
0.24%

Financial Snapshot

Enterprise Value
₹21,088.33 Cr
Total Revenue (TTM)
₹2,519.27 Cr
EBITDA
₹1,042.88 Cr
Free Cash Flow
₹942.34 Cr
Operating Cash Flow
₹967.57 Cr
Shares Outstanding
₹4.57 Cr
Gross Margin
64.79%
Payout Ratio
21.78%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 PFIZER Pfizer Limited NIFTY_SMALLNSEPHARMA 4,609.70 29.19 ₹21,088.33 Cr 1.53% 22.94% 17.19% 1.32% 5.01%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,899.00 39.73 ₹4.56 L Cr 0.82% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,100.00 94.06 ₹2.42 L Cr 0.36% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,857.00 75.99 ₹1.64 L Cr 0.77% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,650.00 64.10 ₹1.24 L Cr 0.22% 19.20% 20.48% 14.85% 33.34%
6 LENSKART LENSKART SOLUTIONS LTD NIFTY_MIDNSEPHARMA 684.90 236.17 ₹1.19 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,120.00 22.36 ₹1.13 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,385.00 28.85 ₹1.12 L Cr 0.88% 14.86% 11.27% 7.23% 11.45%
9 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 1,840.00 111.85 ₹99,333.61 Cr 0.13% 19.53% 16.77% 3.77% 4.00%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue 591.91 Cr603.05 Cr642.34 Cr645.03 Cr629.23 Cr653.17 Cr
Cost of Revenue 202.48 Cr211.23 Cr227.95 Cr224.77 Cr220.36 Cr240.11 Cr
Gross Profit 389.43 Cr391.82 Cr414.39 Cr420.26 Cr408.87 Cr413.06 Cr
Operating Expenses 178.33 Cr196.21 Cr198.74 Cr206.33 Cr187.70 Cr179.76 Cr
Operating Income 211.10 Cr195.61 Cr215.65 Cr213.93 Cr221.17 Cr233.30 Cr
EBITDA 444.89 Cr277.19 Cr271.78 Cr208.20 Cr285.71 Cr292.40 Cr
Interest Expense 2.69 Cr3.25 Cr2.13 Cr1.99 Cr2.11 Cr1.46 Cr
Pretax Income 425.80 Cr259.53 Cr255.37 Cr191.95 Cr268.82 Cr276.68 Cr
Tax Provision 94.86 Cr67.78 Cr66.35 Cr50.11 Cr69.00 Cr72.21 Cr
Net Income 330.94 Cr191.75 Cr189.02 Cr141.84 Cr199.82 Cr204.47 Cr
Diluted EPS 72.3441.9141.3231.0143.6844.69

Profit & Loss (Annual)

Figures in INR.

Metric Nov 2006Nov 2007Nov 2008Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 664.00 Cr676.00 Cr678.00 Cr-2,422.32 Cr2,192.69 Cr2,281.00 Cr2,519.27 Cr
Cost of Revenue ----875.65 Cr795.23 Cr813.06 Cr887.16 Cr
Gross Profit ----1,546.67 Cr1,397.46 Cr1,467.94 Cr1,632.11 Cr
Operating Expenses 537.00 Cr815.00 Cr760.00 Cr-837.89 Cr820.40 Cr786.66 Cr785.02 Cr
Operating Income 114.00 Cr-149.00 Cr-93.00 Cr-708.78 Cr577.06 Cr681.28 Cr847.09 Cr
EBITDA 127.00 Cr-139.00 Cr-82.00 Cr-942.91 Cr823.76 Cr1,085.29 Cr1,042.88 Cr
Interest Expense 000-13.39 Cr15.41 Cr8.41 Cr9.48 Cr
Pretax Income 163.00 Cr451.00 Cr419.00 Cr-824.01 Cr746.07 Cr1,016.09 Cr975.67 Cr
Tax Provision 57.05 Cr112.75 Cr121.51 Cr-200.08 Cr194.74 Cr248.49 Cr253.24 Cr
Net Income 106.00 Cr340.00 Cr300.00 Cr-623.93 Cr551.33 Cr767.60 Cr722.43 Cr
Diluted EPS 35.64113.94100.39133.89136.38120.51167.79157.92

Balance Sheet (Annual)

Figures in INR.

Metric Nov 2006Nov 2007Nov 2008Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 646.00 Cr867.00 Cr1,098.00 Cr-4,000.73 Cr4,228.78 Cr4,911.11 Cr4,921.88 Cr
Current Assets ----2,525.09 Cr2,769.56 Cr3,512.85 Cr3,803.22 Cr
Cash & Equivalents ----36.60 Cr112.00 Cr495.07 Cr102.66 Cr
Inventory ----417.70 Cr433.69 Cr475.92 Cr472.66 Cr
Receivables ----151.73 Cr187.61 Cr193.09 Cr181.80 Cr
Total Liabilities ----793.43 Cr633.24 Cr693.70 Cr718.98 Cr
Current Liabilities ----657.35 Cr546.56 Cr569.51 Cr627.48 Cr
Long Term Debt --------
Total Debt 000-134.47 Cr94.54 Cr108.40 Cr70.23 Cr
Total Equity 406.00 Cr650.00 Cr901.00 Cr-3,207.30 Cr3,595.54 Cr4,217.41 Cr4,202.90 Cr
Shares Outstanding ----4.57 Cr4.57 Cr4.57 Cr4.57 Cr

Cash Flows (Annual)

Figures in INR.

Metric Nov 2006Nov 2007Nov 2008Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 123.00 Cr17.00 Cr238.00 Cr-355.68 Cr256.84 Cr659.75 Cr967.57 Cr
Investing Cash Flow 7.00 Cr232.00 Cr-79.00 Cr--36.05 Cr53.70 Cr-71.34 Cr-561.67 Cr
Financing Cash Flow -34.00 Cr-76.00 Cr-95.00 Cr--345.79 Cr-235.14 Cr-205.34 Cr-798.31 Cr
Capital Expenditure -3.00 Cr266.00 Cr-25.00 Cr--64.98 Cr-18.93 Cr-28.15 Cr-25.23 Cr
Free Cash Flow 120.00 Cr283.00 Cr213.00 Cr-290.70 Cr237.91 Cr631.60 Cr942.34 Cr
Net Change in Cash 97.00 Cr173.00 Cr64.00 Cr--26.16 Cr75.40 Cr383.07 Cr-392.41 Cr

Ratios (Annual)

Figures in %.

Metric Nov 2006Nov 2007Nov 2008Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % ----63.9%63.7%64.4%64.8%
Operating Margin % 17.2%-22.0%-13.7%-29.3%26.3%29.9%33.6%
Net Margin % 16.0%50.3%44.2%-25.8%25.1%33.7%28.7%
ROE % 26.1%52.3%33.3%-19.5%15.3%18.2%17.2%
ROCE % ----21.2%15.7%15.7%19.7%

Shareholding Pattern

Insiders
66.95%
Institutions
17.31%
Public Float
52.39%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for PFIZER

Google News Mon, 07 Sep 2026

This Is What I'd Do With Pfizer Stock Right Now - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxPQkVRblBPUVlybzhTMkZILXdIVmpRU1FwY1VWVTdFcG52V3FEOVo5dHBJUTJYbThJZ3lXeWpydjJYNktKX091bkpFbWhHV1dlazJrMDlfSURDMHQ0ak4xTnFTLU1OX3ltcUxUN01GbExVVUQ0ODdOWm15MUxGV09ScEJxWDNjcWNFbTQ1dw…

Google News Mon, 07 Sep 2026

Forget the Dividend. This Could Be the Real Reason to Buy Pfizer Stock Now - 24/7 Wall St.

<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxQTVdkYW9MLWNoZVBGdENBVGhlQWpKRGdkRHN3V0ZCTzJyNVU1UjMzRU1CcFNFX1BZeFZCOWVJaGdnNHk1T2JDbkxWU0dtSFhwaERYUHdSaTg0MmI1OTNsLXNZeGNfeUtqblBZT3I3MWF5VXFRM3hROG5aY1RBVEtpLUxJakozaWZ1QkVpbm…

Google News Mon, 07 Sep 2026

Pfizer’s Lyme disease vaccine shows 70% efficacy; Texas man sentenced to 12.5 years in $61.5M Medicare telemarketing fraud scheme; Novo Nordisk launches Wegovy subscription model – Morning Medical Update - medicaleconomics.com

<a href="https://news.google.com/rss/articles/CBMi1gJBVV95cUxPVnU1X0hLdnNoem8xSWwtUm9LQ28wXzM4aUFsUUN2U1ZsM0Fwb2dIWmNPdGphRVd3cm9RUzBtT0gzYVlyYUV5aHBnOEt4ck9CVnV0NEs5NTJkV2d1WnZSaGs3bUJYUHlzVVBMV2xwRDhnakZiWVlkNG5kTFBmTm0zNHJGNDlhdHhNcVNEQU…

Google News Mon, 07 Sep 2026

Pfizer stock offers 13.8% upside plus a 5.91% d... - Pluang

<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxPaUtCMlNNQVZlVS1xOVZsblZlTFZGN2xURzVsM2FwcktNLW12SE9fUUZRSFdUN3pPalgtQXZHbXA0Mnczek9jQWgzUXZ4enJhUHdpQUZjNTNvaDdvNllWY0F3WTVoQWlXa1hrQTRqM0lxRWRHMjJIMDJEbHpZa2NMRmwta3M5elhGd0pPdA…

Google News Mon, 07 Sep 2026

Forget the Dividend. This Could Be the Real Reason to Buy Pfizer Stock Now - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxNWTktQTd5Nnd3MFVRWmtvMFBVRHRRSWRYdWp1V3VEaEFIWm9UT3FuRVJyS0dmRGpGMHNvdV9jYlhpaEZSam11cFdEeXdydEltdjcybUVvUG9MLXJtQlkwQkphVFRGdUozRkxoTFFrVS1rdGI5ZzZVaV9NRk55WWFOZWdxRjZuOGRkWkdfT3…

Google News Wed, 02 Sep 2026

Can AI Save Pfizer Stock Before Its Patent Cliff Hits? - Trefis

<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxQWXpDVlBOaXFtQlluYVc2RWdSZG5TZEVvNzVOR1dkTk8yTDJZazVMWmd0V2RWTTV4aTFsaTRDdjhnalBzQnJULXBMSHZTNVFkRkNVVlRrUmdxdms1b2kxc0lzTDNTRmJXTXJ3VHhTd0pQTmpmUy1idHI4aUxzSUZ3VVJvYkR6MGI0ZEtLcU…

PFIZER — Frequently Asked Questions

What is the current share price of Pfizer Limited (PFIZER)?

As of 2026-09-08 04:53 IST, Pfizer Limited (PFIZER) trades at ₹4,609.70 on NSE. Its 52-week range is ₹4,334.58 to ₹5,674.44.

What is the market capitalisation of PFIZER?

Pfizer Limited (PFIZER) has a market capitalisation of ₹21,088.33 Cr on NSE.

What is the P/E ratio of PFIZER?

PFIZER trades at a trailing price-to-earnings (P/E) ratio of 29.19. The industry average P/E is 41.64. Its price-to-book (P/B) ratio is 5.31.

Does PFIZER pay a dividend?

Pfizer Limited (PFIZER) currently offers a dividend yield of 1.53%.

What is the return on equity (ROE) of PFIZER?

PFIZER has a return on equity (ROE) of 17.19%. Its return on capital employed (ROCE) is 22.94%.

Is PFIZER a good stock to buy?

This page provides a data-driven analysis of Pfizer Limited (PFIZER), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space